Doxorubicin Market Report 2026

The doxorubicin market size has grown strongly in recent years. It will grow from $1.42 billion in 2025 to $1.52 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing global cancer prevalence, widespread clinical acceptance of anthracyclines, expansion of hospital oncology infrastructure, growth in chemotherapy-based treatment protocols, strong inclusion in national cancer guidelines.

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising demand for cost-effective cancer therapies, growth of liposomal and targeted drug delivery systems, expanding access to cancer care in developing regions, increasing approvals of generic formulations, higher investment in oncology drug manufacturing. Major trends in the forecast period include rising adoption of liposomal doxorubicin formulations, increasing use in combination chemotherapy regimens, growing demand for generic and biosimilar anthracyclines, expansion of oncology treatment in emerging markets, improved safety and cardiotoxicity management protocols.

The rising prevalence of cancer is anticipated to drive the expansion of the doxorubicin market in the coming years. Cancer is a group of diseases characterized by the abnormal and uncontrolled growth of cells. Doxorubicin is a widely used chemotherapeutic antibiotic indicated for the treatment of various types of cancer, as it inhibits cancer cell proliferation by damaging their DNA. The increasing incidence of cancer has resulted in higher demand for doxorubicin-based therapies. For example, in January 2024, according to data published by the American Cancer Society, a US-based non-profit organization, the United States is expected to record approximately 2,001,140 new cancer cases and 611,720 cancer-related deaths in 2024, compared with 1,958,310 new cases and 609,820 deaths in 2023. As a result, the growing number of cancer patients is contributing to the growth of the doxorubicin market.

Major companies operating in the doxorubicin market are concentrating on the development of innovative chemotherapy products to improve treatment effectiveness while reducing adverse effects for cancer patients. Chemotherapy drugs are designed to target and destroy rapidly dividing cancer cells, although they may also affect healthy cells, leading to side effects; ongoing advancements aim to enhance drug targeting and minimize these impacts. For instance, in August 2024, Lupin Limited, an India-based pharmaceutical company, introduced Doxorubicin Hydrochloride Liposome Injection. This formulation is used in the treatment of advanced ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Its liposomal delivery system enables more targeted drug distribution, which helps reduce systemic toxicity and improve patient tolerability, thereby enhancing overall treatment outcomes in oncology care.

In March 2024, Johnson & Johnson, a US-based company engaged in the research, development, manufacturing, and commercialization of pharmaceutical products and medical devices, acquired Ambrx Biopharma, Inc. for approximately $2 billion. Through this acquisition, Johnson & Johnson aims to strengthen its capabilities in developing next-generation antibody-drug conjugates, particularly for prostate cancer, a key therapeutic focus area. Ambrx Biopharma, Inc. is a US-based company specializing in the development of advanced antibody-drug conjugates for multiple cancer indications.

Major companies operating in the doxorubicin market are Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd.

North America was the largest region in the doxorubicin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the doxorubicin market by increasing costs across active pharmaceutical ingredients, sterile injectables, and specialized manufacturing inputs used in oncology drugs. These measures have impacted production economics and pricing, particularly affecting injectable and liposomal formulations and hospital pharmacy supply chains. Regions heavily dependent on imported APIs, such as Asia-Pacific and parts of Europe, are most affected due to supply chain disruptions. At the same time, tariffs have encouraged local manufacturing, regional sourcing strategies, and investments in domestic pharmaceutical production, supporting long-term supply resilience.

The doxorubicin market research report is one of a series of new reports that provides doxorubicin market statistics, including doxorubicin industry global market size, regional shares, competitors with a doxorubicin market share, detailed doxorubicin market segments, market trends and opportunities, and any further data you may need to thrive in the doxorubicin industry. This doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Doxorubicin is an anthracycline antibiotic used in cancer therapy due to its strong antitumor activity. It is prescribed for the treatment of various cancers, including breast cancer, lung cancer, and hematological malignancies. The drug works by inhibiting DNA replication, which prevents cancer cells from dividing and proliferating.

The main forms of doxorubicin drugs include lyophilized powder and doxorubicin injection. Lyophilized doxorubicin powder is a freeze-dried form of the chemotherapy drug in which water content is removed to enhance stability and extend shelf life. This formulation improves preservation and storage of the drug. Doxorubicin products are used in the treatment of breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and other cancers, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The doxorubicin market consists of sales of doxorubicin hydrochloride injections, adriamycin, doxil, myocet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.